Vertex Pharmaceuticals has won approval in Europe for its next-generation cystic fibrosis therapy Alyftrek ...

Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Alyftrek is approved to treat people ages 6 and older who have the genetic condition called cystic fibrosis. Cystic fibrosis happens because of a change in a gene on chromosome 7.

ALYFTREK and TRIKAFTA are not recommended in patients with moderate hepatic impairment and should only be considered when there is a clear medical need and benefit outweighs risk.

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has approved ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis transmembrane ...

Alyftrek and Journavx — The Two Big Launches. According to JPMorgan analyst Jessica Fye, investors will be laser-focused on the company’s two big launches: Alyftrek and Journavx.

ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced ...

ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced ...

ALYFTREK. There are no available safety data for ALYFTREK in patients who previously discontinued or interrupted treatment with drugs containing ELX, TEZ, or IVA due to adverse reactions.